https://www.live-feeds.com/feed/argenx-to-acquire-unnatural-products-in-deal-worth-up-to-1-15bContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/argenx-to-acquire-unnatural-products-in-deal-worth-up-to-1-15bhttps://www.live-feeds.com/feed/argenx-to-acquire-unnatural-products-in-deal-worth-up-to-1-15b#u198471Fri, 13 Nov 2026 08:45:48 +0000Biopharmaceutical company Argenx has agreed to acquire Unnatural Products in a transaction valued at up to $1.15 billion. The buyout gives Argenx control of an artificial intelligence-guided macrocycle discovery platform. By integrating this platform with its own antibody engineering expertise, Argenx aims to expand its capabilities in oral peptides and next-generation immunology medicines. The deal positions the company to develop macrocyclic peptide drugs that can target complex biological pathways previously difficult to reach with traditional biologics.Why it mattersThe acquisition represe